Canterbury DHB
By definition, all patients carry the BCR-ABL fusion gene, which is typically the result of the t(9;22). The fusion gene produces an abnormal tyrosine kinase, an oncoprotein which varies in size (p190, p210, p230). About 5–10% of patients do not have the typical t(9;22) or Philadelphia chromosome on karyotyping, but the BCR/ABL fusion is detectable by molecular methods (PCR or FISH). Their prognosis and response to treatment is no different from other CML patients.
Topic Code: 6211